A directory of where to buy chemicals in the USA, including: distributors, industrial manufacturers, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the suppliers website for prices or more information.
| Product | Description | |
|---|---|---|
| GSK-3 inhibitor 1 | GSK-3 inhibitor 1 is a potent GSK-3 inhibitor. Grades: >98%. CAS No. 603272-51-1. Molecular formula: C22H17ClFN5O2. Mole weight: 437.85. |  |
| GSK-3 inhibitor 3 | GSK-3 inhibitor 3 is a selective, orally active and brain-penetrant inhibitor of GSK-3 , with IC 50 s of 0.35 nM and 0.25 nM for GSK-3α and GSK-3β, respectively. GSK-3 inhibitor 3 lowers levels of tau protein phosphorylation at S396 in a triple-transgenic mouse Alzheimers disease model, with IC 50 of 10 nM. GSK-3 inhibitor 3 can be used for neurological disease research [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 2227279-84-5. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-154851. |  |
| GSK-3 Inhibitor, AR-A014418, (N-[(4-Methoxyphenyl)methyl]-N-(5-nitro-2-thiazolyl)urea) | Cell-permeable. A selective glycogen synthase kinase 3 (GSK-3) inhibitor (IC50 = 104nm). Inhibition is competitive with respect to ATP (Ki = 38nm). Exhibits specificity for GSK-3 over cdk2 and cdk5 (IC50 values are > 100 =um) and over 26 other kinases. Inhibits b-amyloid-mediated neurodegeneration in hippocampal slices. Group: Biochemicals. Grades: Highly Purified. Pack Sizes: 2mg. Molecular Formula: C??H??N?O?S. US Biological Life Sciences. |  Worldwide |
| GSK-3? Inhibitor I - CAS 327036-89-5 | The GSK-3? Inhibitor I, also referenced under CAS 327036-89-5, controls the biological activity of GSK-3?. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications. Group: Fluorescence/luminescence spectroscopy. |  |
| GSK-3? Inhibitor II - CAS 478482-75-6 | The GSK-3? Inhibitor II, also referenced under CAS 478482-75-6, controls the biological activity of GSK-3?. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications. Group: Fluorescence/luminescence spectroscopy. | |
| GSK 3 Inhibitor IX | GSK 3 Inhibitor IX (6-Bromoindirubin-3'-oxime; BIO) is a potent, selective, reversible and ATP-competitive inhibitor of GSK-3?/? and CDK1-cyclinB complex with IC50s of 5 nM/320 nM/80 nM for (GSK-3?/?)/CDK1/CDK5, respectively. Uses: Scientific research. Group: Signaling pathways. Alternative Names: 6-Bromoindirubin-3'-oxime; BIO; MLS 2052. CAS No. 667463-62-9. Pack Sizes: 10 mM * 1 mL; 1 mg; 5 mg; 10 mg; 50 mg. Product ID: HY-10580. | |
| GSK-3 Inhibitor IX ((2Z,3E)-6-Bromoindirubin-3-oxime) | A cell-permeable bis-indolo (indirubin) compound that acts as a highly potent, selective, reversible, and ATP-competitive inhibitor of GSK-3a/b (IC50=5nM). Its specificity has been tested against various Cdk's (IC50=83, 300, 320, and 10,000nM for Cdk5/p25, Cdk2/A, Cdk1/B, and Cdk4/D1, respectively) as well as many other commonly studied kinases (IC50≥10uM), including MAP kinases, PKA, PKC isoforms, PKG, CK, and IRTK. Inhibition of GSK by BIO has been shown to result in the activation of Wnt-signaling pathway and sustained pluripotency in human and murine ESCs (embryonic stem cells). Reported to maintain self-renewal in human and mouse embryonic stem cells. Also induces the differentiation of neonatal cardiomyocytes. Group: Biochemicals. Grades: Highly Purified. CAS No. 667463-62-9. Pack Sizes: 1mg, 10mg. US Biological Life Sciences. | Worldwide |
| GSK-3 Inhibitor IX - CAS 667463-62-9 | BIO, CAS 667463-62-9, is a cell-permeable, highly potent, selective, reversible, and ATP-competitive inhibitor of GSK-3?/? (IC?? = 5 nM). Maintains self-renewal in human & mouse embryonic stem cells. Group: Fluorescence/luminescence spectroscopy. | |
| GSK-3 Inhibitor IX, Control, MeBIO - CAS 710323-61-8 | The GSK-3 Inhibitor IX, Control, MeBIO, also referenced under CAS 710323-61-8, controls the biological activity of GSK-3. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications. Group: Fluorescence/luminescence spectroscopy. | |
| GSK-3? Inhibitor VI - CAS 62673-69-2 | The GSK-3? Inhibitor VI, also referenced under CAS 62673-69-2, controls the biological activity of GSK-3?. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications. Group: Fluorescence/luminescence spectroscopy. | |
| GSK-3? Inhibitor VIII - CAS 487021-52-3 | The GSK-3? Inhibitor VIII, also referenced under CAS 487021-52-3, controls the biological activity of GSK-3?. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications. Group: Fluorescence/luminescence spectroscopy. | |
| GSK-3 Inhibitor X - CAS 740841-15-0 | The GSK-3 Inhibitor X, also referenced under CAS 740841-15-0, controls the biological activity of GSK-3. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications. Group: Fluorescence/luminescence spectroscopy. | |
| GSK-3? Inhibitor XI - CAS 626604-39-5 | The GSK-3? Inhibitor XI, also referenced under CAS 626604-39-5, controls the biological activity of GSK-3?. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications. Group: Fluorescence/luminescence spectroscopy. | |
| GSK3 Inhibitor XIII | GSK3 Inhibitor XIII is a potent and ATP-competitive inhibitor of glycogen synthase kinase 3 (GSK3). Synonyms: Glycogen Synthase Kinase 3 Inhibitor XIII; 5,6,7,8-tetrahydro-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl-4-quinazolinamine. Grades: ≥98%. CAS No. 404828-08-6. Molecular formula: C18H19N5. Mole weight: 305.4. | |
| GSK-3 Inhibitor XIII - CAS 404828-08-6 | The GSK-3 Inhibitor XIII, also referenced under CAS 404828-08-6, controls the biological activity of GSK-3. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications. Group: Fluorescence/luminescence spectroscopy. | |
| GSK-3? Inhibitor XII, TWS119 - CAS 601514-19-6 | The GSK-3? Inhibitor XII, TWS119, also referenced under CAS 601514-19-6, controls the biological activity of GSK-3?. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications. Group: Fluorescence/luminescence spectroscopy. | |
| GSK3? Inhibitor XIX, IM-12 | The GSK3? Inhibitor XIX, IM-12 controls the biological activity of GSK3?. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications. Group: Fluorescence/luminescence spectroscopy. | |
| GSK-3 Inhibitor XV | The GSK-3 Inhibitor XV controls the biological activity of GSK-3. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications. Group: Fluorescence/luminescence spectroscopy. | |
| GSK3 Inhibitor XV | GSK3 inhibitor XV is a racemic mixture of (R)-GSK3 inhibitor XV and (S)-GSK3 inhibitor XV. (R)-GSK3 inhibitor XV inhibits glycogen synthase kinase (GSK) 3α and β with IC50 values of 0.35 and 0.55 nM respectively. (S)-GSK3 inhibitor XV is less potent than the (R)-GSK3 inhibitor XV. Synonyms: [11-bromo-9-hydroxypyrido[2, 3-a]pyrrolo[3, 4-c]carbazole-5, 7(1H, 6H)-dionato-κN1, κN12]carbonyl[(1, 2, 3, 4, 5-η)-1-(methoxycarbonyl)-2, 4-cyclopentadien-1-yl]-ruthenium. Grades: ≥98%. CAS No. 936112-69-5. Molecular formula: C25H14BrN3O6Ru. Mole weight: 633.40. | |
| GSK-3 Inhibitor XVI - CAS 252917-06-9 | GSK-3 Inhibitor XVI - CAS 252917-06-9, is a cell-permeable, potent, ATP-competitive, and highly selective GSK-3 inhibitor (IC?? = 10 and 6.7 nM against GSK-3? and GSK-3?, respectively). Group: Fluorescence/luminescence spectroscopy. | |
| GSK-3? Inhibitor XVIII - CAS 1139875-74-3 | The GSK-3? Inhibitor XVIII, also referenced under CAS 1139875-74-3, controls the biological activity of GSK-3?. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications. Group: Fluorescence/luminescence spectroscopy. | |
| GSK-3? Inhibitor XXIV - CAS 1005201-24-0 | The GSK-3? Inhibitor XXIV, also referenced under CAS 1005201-24-0, controls the biological activity of GSK-3?. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications. Group: Fluorescence/luminescence spectroscopy. | |
| GSK-3? Inhibitor XXV | The GSK-3? Inhibitor XXV controls the biological activity of GSK-3?. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications. Group: Fluorescence/luminescence spectroscopy. | |
| GSK-3? Inhibitor XXVII | The GSK-3? Inhibitor XXVII controls the biological activity of GSK-3?. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications. Group: Fluorescence/luminescence spectroscopy. | |
| GSK-3? Peptide Inhibitor, Cell-permeable | The GSK-3? Peptide Inhibitor, Cell-permeable controls the biological activity of GSK-3?. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications. Group: Fluorescence/luminescence spectroscopy. | |
| GSK4027 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| GSK4027 | GSK4027 is a potent and selective inhibitor of p300/CBP-associated factor (PCAF)/general control nonderepressible 5 (GCN5) bromodomain (Ki = 1.4 nM; IC50 = 60 nM in a chromatin engagement assay). Synonyms: 4-bromo-2-methyl-5-[[(3R,5R)-1-methyl-5-phenyl-3-piperidinyl]amino]-3(2H)-pyridazinone. Grades: ≥95%. CAS No. 2079896-25-4. Molecular formula: C17H21BrN4O. Mole weight: 377.3. | |
| GSK 4027 | GSK 4027 is a chemical probe for the PCAF/GCN5 bromodomain with an pIC50 of 7.4±0.11 for PCAF in a time-resolved fluorescence resonance energy transfer (TR-FRET) assay. Uses: Scientific research. Group: Signaling pathways. CAS No. 2079896-25-4. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-101027. | |
| GSK4028 | ?97% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| GSK4112 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| GSK4112 | GSK 4112, a kind of synthetic agonist of REV-ERBα, could suppress the expression of sorts of genes involved in gluconeogenesis. IC50: 0.4 μM (EC50). Uses: Gsk 4112 is a kind of synthetic agonist of rev-erbα and could suppress the expression of sorts of genes involved in gluconeogenesis. Synonyms: GSK4112; GSK 4112; GSK-4112. SR6452;CHEMBL1961795;1216744-19-2;MLS006010708;GTPL2903. Grades: 95%. CAS No. 1216744-19-2. Molecular formula: C18H21ClN2O4S. Mole weight: 396.89. | |
| GSK 4112 | GSK 4112. Group: Biochemicals. Grades: Purified. CAS No. 1216744-19-2. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. | Worldwide |
| GSK429286A | GSK429286A is a selective inhibitor of ROCK1 with an IC50 value of 14 nM. Uses: Scientific research. Group: Signaling pathways. CAS No. 864082-47-3. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-11000. | |
| GSK429286A | GSK429286A is a selective inhibitor of ROCK1 and ROCK2 with IC50 of 14 nM and 63 nM, respectively. Uses: Reprogramming, self-renewal. Synonyms: GSK 429286A; GSK-429286A. Grades: 0.98. CAS No. 864082-47-3. Molecular formula: C21H16F4N4O2. Mole weight: 432.37. | |
| GSK4418959 | GSK4418959 (IDE275) is a non-covalent, reversible, selective and orally active WRN helicase inhibitor. GSK4418959 inhibits ATPase and DNA unwinding functions in an ATP-competitive manner. GSK4418959 can be used for the study of microsatellite instability-high (MSI-H) cancer[1]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: IDE275. CAS No. 3064599-36-3. Pack Sizes: 1 mg; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-169422. | |
| GSK461364 | GSK461364 is a selective, reversible and ATP-competitive Polo-like kinase 1 (PLK1) inhibitor with a Ki value of 2.2 nM. Uses: Scientific research. Group: Signaling pathways. Alternative Names: GSK461364A. CAS No. 929095-18-1. Pack Sizes: 10 mM * 1 mL; 1 mg; 5 mg; 10 mg; 50 mg; 100 mg; 200 mg. Product ID: HY-50877. | |
| GSK461364 | GSK461364 is a selective, reversible and ATP-competitive Polo-like kinase 1 (PLK1) inhibitor with a Ki value of 2.2 nM. Uses: Designed for use in research and industrial production. Additional or Alternative Names: 5-[6-[(4-Methyl-1-piperazinyl)methyl]-1h-benzimidazol-1-yl]-3-[(1r)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thiophenecarboxamide. Product Category: Inhibitors. Appearance: White to Beige Powder. CAS No. 929095-18-1. Molecular formula: C27H28N5O2F3S. Mole weight: 543.6. Purity: 0.96. Product ID: ACM929095181. Alfa Chemistry ISO 9001:2015 Certified. |  |
| GSK-461364 | GSK-461364 is a Polo-like kinase 1 inhibitor, is also a small molecule Polo-like kinase 1 (PLK1) inhibitor with potential antineoplastic activity. Polo-like kinase 1 inhibitor GSK461364 selectively inhibits Plk1, inducing selective G2/M arrest followed by apoptosis in a variety of tumor cells while causing reversible cell arrest at the G1 and G2 stage without apoptosis in normal cells. Plk1, named after the polo gene of Drosophila melanogaster, is a serine/threonine protein kinase involved in regulating mitotic spindle function in a non-ATP competitive manner. Synonyms: GSK461364; GSK 461364; GSK-461364; GSK461364A; GSK 461364A; GSK-461364A. 5-[6-[(4-Methyl-1-piperazinyl)methyl]-1h-benzimidazol-1-yl]-3-[(1r)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thiophenecarboxamide. CAS No. 929095-18-1. Molecular formula: C27H28F3N5O2S. Mole weight: 543.609. | |
| GSK-461364 | GSK-461364 is a Polo-like kinase 1 inhibitor, is also a small molecule Polo-like kinase 1 (PLK1) inhibitor with potential antineoplastic activity. Polo-like kinase 1 inhibitor GSK461364 selectively inhibits Plk1, inducing selective G2/M arrest followed by apoptosis in a variety of tumor cells while causing reversible cell arrest at the G1 and G2 stage without apoptosis in normal cells. Plk1, named after the polo gene of Drosophila melanogaster, is a serine/threonine protein kinase involved in regulating mitotic spindle function in a non-ATP competitive manner. Uses: Designed for use in research and industrial production. Additional or Alternative Names: GSK461364; GSK 461364; GSK-461364; GSK461364A; GSK 461364A; GSK-461364A. Product Category: Inhibitors. Appearance: White solid powder. CAS No. 929095-18-1. Molecular formula: C27H28F3N5O2S. Mole weight: 543.6. Purity: >98%. IUPACName: (R)-5-(6-((4-methylpiperazin-1-yl)methyl)-1H-benzo[d]imidazol-1-yl)-3-(1-(2-(trifluoromethyl)phenyl)ethoxy)thiophene-2-carboxamide. Canonical SMILES: O=C(C1=C(O[C@@H](C2=CC=CC=C2C(F)(F)F)C)C=C(N3C=NC4=CC=C(CN5CCN(C)CC5)C=C34)S1)N. Product ID: ACM929095181-2. Alfa Chemistry ISO 9001:2015 Certified. | |
| GSK461364A | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| GSK 461364 analogue I | GSK 461364 analogue I is a potent polo-like kinase (PLK) inhibitor with selectivity for PLK1 (IC50: 2 nM) over PLK3 (IC50: 630 nM). Synonyms: GSK 461364 analogue I; GSK461364 analogue I; GSK-461364 analogue I; GSK579289A; GSK 579289A; GSK-579289A. Compound 25 [PMID 19237286]; 3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-[6-(1-methylpiperidin-4-yl)oxybenzimidazol-1-yl]thiophene-2-carboxamide. Grades: 99%. CAS No. 929095-23-8. Molecular formula: C26H27ClN4O3S. Mole weight: 511.04. | |
| GSK 461364 analogue II | GSK 461364 analogue II is a potent polo-like kinase (PLK) inhibitor with selectivity for PLK1 (IC50: 2 nM) over PLK3 (IC50: 270 nM). Synonyms: GSK 461364 analogue II; GSK461364 analogue II; GSK-461364 analogue II; 5-[6- (1-methylpiperidin-4-yl) oxybenzimidazol-1-yl]-3-[ (1R) -1-[2- (trifluoromethyl) phenyl]ethoxy]thiophene-2-carboxamide. Grades: 99%. CAS No. 929095-22-7. Molecular formula: C27H27F3N4O3S. Mole weight: 544.59. | |
| GSK466317A | GSK466317A is a G-Protein-Coupled Receptor Kinase 2 (GRK2) Inhibitor. Synonyms: GSK466317A; GSK-466317A; GSK 466317A. N-(7-chloro-1H-indazol-5-yl)-6-methyl-2-oxo-4-[4-(trifluoromethyl)phenyl]-3,4-dihydro-1H-pyridine-5-carboxamide. Grades: 98%. CAS No. 864082-48-4. Molecular formula: C21H16ClF3N4O2. Mole weight: 448.83. | |
| GSK467 | GSK467 is a cell penetrant and selective KDM5B (JARID1B or PLU1) inhibitor with a Ki of 10 nM and an IC50 of 26 nM. GSK467 shows 180-fold selectivity for KDM4C and no measurable inhibitory effects toward KDM6 or other Jumonji family members[1][2]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1628332-52-4. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-116761. | |
| GSK 4716 | GSK 4716 is a selective agonist of estrogen-related receptors ERRβ and ERRγ displaying selectivity over ERRα and the classical estrogen receptors. Activation of GSK 4716 regulates mitochondrial activity in skeletal muscle during exercise. Synonyms: GSK4716; GSK 4716; GSK-4716; 4-Hydroxy-2-[ (1E) -[4- (1-methylethyl) phenyl]methylene]hydrazide. Grades: ≥99% by HPLC. CAS No. 101574-65-6. Molecular formula: C17H18N2O2. Mole weight: 282.34. | |
| GSK 4716 | GSK 4716. Group: Biochemicals. Grades: Purified. CAS No. 101574-65-6. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. | Worldwide |
| GSK481 | GSK481 is a potent inhibitor of Receptor-interacting serine/threonine-protein kinase 1 (RIPK1 or RIP1; IC50 value 2.8 nM for inhibition of Ser166 autophosphorylation of hWT RIP1) with preference for RIP1 over 450 other kinases. Synonyms: GSK481; GSK-481; GSK 481. 5-benzyl-N-[(3S)-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-1,2-oxazole-3-carboxamide. Grades: 98%. CAS No. 1622849-58-4. Molecular formula: C21H19N3O4. Mole weight: 377.39. | |
| GSK484 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| GSK-484 | GSK-484 is a potent protein-arginine deiminase type-4 (PAD-4) inhibitor. Synonyms: GSK484; GSK 484. Grades: ≥98% by HPLC. CAS No. 1652629-23-6. Molecular formula: C27H31N5O3. Mole weight: 473.6. | |
| GSK484 hydrochloride | GSK484 hydrochloride is a selective and reversible peptidylarginine deiminase 4 (PAD4) inhibitor. GSK484 hydrochloride demonstrates high affinity binding to PAD4 with IC50s of 50 nM in the absence of Calcium. In the presence of 2 mM Calcium, notably lower potency (250 nM) is observed. Uses: Scientific research. Group: Signaling pathways. CAS No. 1652591-81-5. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg; 200 mg; 500 mg. Product ID: HY-100514. | |
| GSK-503 | GSK-503 is a potent EZH2 inhibitor with potential anticancer activity. Increased activity of the epigenetic modifier EZH2 has been associated with different cancers. Synonyms: GSK503; GSK 503; GSK503. Grades: 98%. CAS No. 1346572-63-1. Molecular formula: C31H38N6O2. Mole weight: 526.67. | |
| GSK5182 | GSK5182 is a specific inverse agonist for estrogen-related receptor γ. Uses: Designed for use in research and industrial production. Additional or Alternative Names: GSK5182; GSK 5182; GSK-5182. Product Category: Agonists. Appearance: Solid powder. CAS No. 877387-37-6. Molecular formula: C27H31NO3. Mole weight: 417.55. Purity: >98%. IUPACName: 4-[(Z)-1-[4-(2-dimethylaminoethoxy)phenyl]-5-hydroxy-2-phenylpent-1-enyl]phenol. Canonical SMILES: OC1=CC=C(/C(C2=CC=C(OCCN(C)C)C=C2)=C(C3=CC=CC=C3)\CCCO)C=C1. Product ID: ACM877387376. Alfa Chemistry ISO 9001:2015 Certified. | |
| GSK525762 | GSK525762A, also known as I-BET-762 and GSK525762, is a small molecule inhibitor of the BET (Bromodomain and Extra-Terminal) family of bromodomain-containing proteins with potential antineoplastic activity. Upon administration, the BET inhibitor GSK525762 binds to the acetylated lysine recognition motifs on the bromodomain of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histone peptides. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of tumor cell growth. Characterized by a tandem repeat of bromodomain at the N-terminus, BET proteins, comprising of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that play an important role during development and cellular growth. Synonyms: GSK525762; GSK525762; GSK525762; GSK525762A; GSK-525762A; GSK 525762A; I-BET-762; I-BET762; I-BET 762; molibresib. CAS No. 1260907-17-2. Molecular formula: C22H22ClN5O2. Mole weight: 423.9. | |
| GSK 525762A | GSK 525762A. Group: Biochemicals. Alternative Names: (4S)-6-(4-Chlorophenyl)-N-ethyl-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine-4-acetamide; I-BET 762. Grades: Highly Purified. CAS No. 1260907-17-2. Pack Sizes: 5mg. Molecular Formula: C22H22ClN5O2, Molecular Weight: 423.9. US Biological Life Sciences. | Worldwide |
| GSK 525762A-d5 | GSK 525762A-d5. Group: Biochemicals. Alternative Names: (4S)-6-(4-Chlorophenyl)-N-ethyl-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine-4-acetamide-d5; I-BET 762-d5. Grades: Highly Purified. Pack Sizes: 1mg. Molecular Formula: C22H17D5ClN5O2, Molecular Weight: 428.93. US Biological Life Sciences. | Worldwide |
| GSK 525768A | GSK 525768A is a enantiomer analogue of GSK 525762A which is a BET family inhibitor aiming at the bromodomain and has potential effect against cancers and sorts of other diseases related to BET bromodomains. Uses: Gsk 525768a is a enantiomer analogue of gsk 525762a which is a bet family inhibitor aiming at the bromodomain and has potential effect against cancers and sorts of other diseases related to bet bromodomains. Synonyms: GSK 525768A; GSK525768A; GSK-525762A; CHEMBL2153435; SCHEMBL12966358; DTXSID50680634. Grades: 98%. CAS No. 1260530-25-3. Molecular formula: C22H22ClN5O2. Mole weight: 423.90. | |
| GSK547 | GSK547 is a highly selective and potent RIP1 (RIPK1) inhibitor which displays 400-fold improvement in mouse pharmacokinetic oral exposure compared with GSK963. Synonyms: RIP1i. Grades: ≥98%. CAS No. 2226735-55-1. Molecular formula: C20H18F2N6O. Mole weight: 396.39. | |
| GSK547 | GSK547 (GSK'547) is a highly selective and potent inhibitor of receptor-interacting serine/threonine protein kinase 1 (RIPK1), inhibits macrophage-mediated adaptive immune tolerance in pancreatic cancer[1]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: GSK'547. CAS No. 2226735-55-1. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg; 200 mg. Product ID: HY-114492. | |
| GSK-5498A | GSK-5498A, a CRAC channel blocker, has been found to have effect in restraining pro-inflammatory cytokine. IC50: 1 uM. Uses: Gsk-5498a is a crac channel blocker that has been found to have effect in restraining pro-inflammatory cytokine. Synonyms: GSK-5498A; GSK5498A; GSK 5498A; 2,6-Difluoro-N-(1-(2-fluoro-6-(trifluoromethyl)benzyl)-1H-pyrazol-3-yl)benzamide. Grades: 97%. CAS No. 1253186-49-0. Molecular formula: C18H11F6N3O. Mole weight: 399.29. | |
| GSK554418A | GSK-554418A is a azaindole Cannabinoid receptor type 2 (CB2) agonist. It can be used for the treatment of chronic pain. Uses: Chronic pain. Synonyms: GSK-554418A; GSK 554418A; GSK554418A. (4-((3-chlorophenyl)amino)-1-methyl-1H-pyrrolo(3,2-C)pyridin-7-yl)-4-morpholinyl- Methanone. Grades: 98%. CAS No. 871819-90-8. Molecular formula: C19H19ClN4O2. Mole weight: 370.84. | |
| GSK575594A | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| GSK583 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| GSK583 | GSK583 is a highly potent, orally active and selective inhibitor of RIP2 Kinase, with IC50 of 5 nM. GSK583 inhibits both TNF-? and IL-6 production with an IC50 value of 200 nM. Uses: Scientific research. Group: Signaling pathways. CAS No. 1346547-00-9. Pack Sizes: 10 mM * 1 mL; 2 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-100339. | |
| GSK583 | GSK583 is a selective receptor-interacting serine/threonine-protein kinase 2 (RIP2 Kinase) inhibitor and the RIP2K binding IC50 is 5 nM. GSK583 can inhibit both TNF-α and IL-6 production with an IC50 value of 200 nM in an ex vivo human translational model. Synonyms: GSK583; GSK 583; GSK-583. 6 - (tert-Butylsulfonyl) - N - (5-fluoro - 1H - indazol-3-yl)quinolin-4-amine. Grades: 98%. CAS No. 1346547-00-9. Molecular formula: C20H19FN4O2S. Mole weight: 398.46. | |
| GSK591 | ?97% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| GSK591 | GSK591, also known as EPZ015866 and GSK3203591, is a chemical probe for PRMT5. In an in vitro biochemical assay, GSK591 potently inhibits the PRMT5/MEP50 complex from methylating (histone) H4 with IC50=11 nM. In Z-138 cells, GSK591 inhibits the symmetric arginine methylation of SmD3 with EC50=56 nM. Further, GSK591 is selective for PRMT5 (up to 50 micromolar) relative to a panel of methyltransferases. (http://www.thesgc.org/chemical-probes/GSK59). Uses: Designed for use in research and industrial production. Additional or Alternative Names: GSK591; GSK-591; GSK 591; EPZ015866; EPZ-015866; EPZ 015866; GSK 3203591; GSK-3203591; GSK3203591. Product Category: Others. Appearance: Solid powder. CAS No. 1616391-87-7. Molecular formula: C22H28N4O2. Mole weight: 380.49. Purity: >98%. IUPACName: (S)-2-(cyclobutylamino)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)isonicotinamide. Canonical SMILES: O=C(NC[C@H](O)CN1CCC(C=CC=C2)=C2C1)C3=CC(NC4CCC4)=NC=C3. Product ID: ACM1616391877. Alfa Chemistry ISO 9001:2015 Certified. Categories: GSK-598809. | |
| GSK591 | GSK591 (EPZ015866) is a potent and selective inhibitor of protein methyltransferase 5 (PRMT5) with an IC50 of 4 nM[1]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: EPZ015866; GSK3203591. CAS No. 1616391-87-7. Pack Sizes: 10 mM * 1 mL; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-100235. | |
| GSK5959 | GSK-5959 is a potent, selective and cell permeable BRPF1 bromodomain inhibitor with IC50 value of 80 nM. It exhibits >100-fold selectivity for BRPF1 over a panel of 35 other bromodomains, including BRPF2/3 and BET family bromodomains. It is used at 10 μM final concentration in various in vitro assays. It disrupts chromatin binding of BRPF1 in a cellular assay by blocking the interaction of BRPF1 with histone H3 in vitro. Uses: Gsk-5959 disrupts chromatin binding of brpf1 in a cellular assay. Synonyms: N-(1,3-dimethyl-2-oxo-6-piperidin-1-ylbenzimidazol-5-yl)-2-methoxybenzamide;GSK-5959; GSK 5959; GSK5959. Grades: >98%. CAS No. 901245-65-6. Molecular formula: C22H26N4O3. Mole weight: 394.47. | |
| GSK 5959 | GSK 5959. Group: Biochemicals. Grades: Purified. CAS No. 901245-65-6. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. | Worldwide |
| GSK-598809 | GSK598809 is a selective Dopamine D3 receptor antagonist originated by GlaxoSmithKline. It may decrease the rewarding effects of contextual cues associated with drug intake preclinically and that may reduce drug craving in humans. No recent development for the treatment of Drug abuse. Eating disorders and Smoking withdrawal was reported. Uses: Drug abuse; eating disorders; smoking withdrawal. Synonyms: GSK-598809; GSK 598809; GSK598809; NII-Y5OZ63HC3V;5-(5-((3-((1S,5R)-1-(2-Fluoro-4-(trifluoromethyl)phenyl)-5-methyl-3-azabicyclo(3.1.0)hexan-3-yl)propyl)thio)-4-methyl-4H-1,2,4-triazol-3-yl)-4-methyloxazole. Grades: 98%. CAS No. 1310803-30-5. Molecular formula: C23H25F4N5OS. Mole weight: 495.54. | |
Our database is helping our users find suppliers everyday.
